Marksans Pharma Ltd
NSE:MARKSANS
Intrinsic Value
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. [ Read More ]
The intrinsic value of one
MARKSANS
stock under the Base Case scenario is
101.48
INR.
Compared to the current market price of 166.85 INR,
Marksans Pharma Ltd
is
Overvalued by 39%.
Marksans Pharma Ltd's market capitalization is 75.6B INR.
MARKSANS stock price is 166.85 INR.
MARKSANS stock (101.48 INR) is 39% less than its price (166.85 INR).
MARKSANS stock (104.87 INR) is 37% less than its price (166.85 INR). Open DCF Valuation
MARKSANS stock (98.08 INR) is 41% less than its price (166.85 INR). Open Relative Valuation
MARKSANS has downside potential of 81% compared to the average analyst price target.
Open Wall St Estimates
MARKSANS has positive Net Income for the last twelve months.
MARKSANS's Revenue has grown by 18% over the past 12 months.
MARKSANS has positive Operating Income for the last twelve months.
MARKSANS's ROE (Return on Equity) for the past 12 months is positive and is equal to 20%.
MARKSANS's ROIC (Return on Invested Capital) has decreased in the last 3 years from 31% to 22%.
MARKSANS's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 22%.
MARKSANS's ROE (Return on Equity) has significantly decreased in the last 3 years from 31% to 20%.
MARKSANS has positive Free Cash Flow for the last twelve months.
MARKSANS's Revenue has been growing by 15% per year for the last 3 years.
MARKSANS has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
MARKSANS has positive three-year average ROIC (Return on Invested Capital): 23%. The company is efficient at using invested capital to generate operating income.
MARKSANS has positive Gross Profit for the last twelve months.
MARKSANS's D/E (Debt to Equity) is very low and is equal to 0.05.
MARKSANS's short-term assets (17B INR) exceed its short-term liabilties (3B INR).
MARKSANS's long-term assets (23B INR) exceed its long-term liabilties (4B INR).
MARKSANS has negative Net Debt. This means that the company has more cash and short-term investments (7B INR) than debt (963m INR).
MARKSANS's Altman Z-Score is very high and is equal to 12.96.
MARKSANS earns more than enough operating income (4B INR) to safely cover interest payments on its debt (50m INR).
Valuation Backtest
Marksans Pharma Ltd
Run backtest to discover the historical profit from buying and selling
MARKSANS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Marksans Pharma Ltd
Balance Sheet Decomposition
Marksans Pharma Ltd
| Current Assets | 17B |
| Cash & Short-Term Investments | 6.7B |
| Receivables | 4.5B |
| Other Current Assets | 5.8B |
| Non-Current Assets | 6.1B |
| PP&E | 4.7B |
| Intangibles | 1.1B |
| Other Non-Current Assets | 313.6m |
| Current Liabilities | 3.3B |
| Accounts Payable | 2B |
| Short-Term Debt | 352.1m |
| Other Current Liabilities | 972m |
| Non-Current Liabilities | 1.1B |
| Long-Term Debt | 610.5m |
| Other Non-Current Liabilities | 442m |
Earnings Waterfall
Marksans Pharma Ltd
|
Revenue
|
21B
INR
|
|
Cost of Revenue
|
-10.1B
INR
|
|
Gross Profit
|
10.9B
INR
|
|
Operating Expenses
|
-7B
INR
|
|
Operating Income
|
3.9B
INR
|
|
Other Expenses
|
-739.9m
INR
|
|
Net Income
|
3.2B
INR
|
Free Cash Flow Analysis
Marksans Pharma Ltd
MARKSANS Profitability Score
Profitability Due Diligence
Marksans Pharma Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Marksans Pharma Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
MARKSANS Solvency Score
Solvency Due Diligence
Marksans Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Marksans Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MARKSANS Price Targets Summary
Marksans Pharma Ltd
According to Wall Street analysts, the average 1-year price target for
MARKSANS
is 31 INR
.
Shareholder Return
MARKSANS Price
Marksans Pharma Ltd
| Average Annual Return | 57.53% |
| Standard Deviation of Annual Returns | 132.9% |
| Max Drawdown | -58% |
| Market Capitalization | 75.6B INR |
| Shares Outstanding | 453 164 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Marksans Pharma Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2002-04-03. The firm operates through the manufacture of pharmaceutical formulation segment. The firm is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. The company marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The firm has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. The company also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The firm has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
MARKSANS
stock under the Base Case scenario is
101.48
INR.
Compared to the current market price of 166.85 INR,
Marksans Pharma Ltd
is
Overvalued by 39%.
You don't have any saved screeners yet
